Do analysts prefer FARN or PRTC?

PureTech Health has a consensus price target of GBX 508, indicating a potential upside of 281.38%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts plainly believe PureTech Health is more favorable than Faron Pharmaceuticals Oy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Faron Pharmaceuticals Oy 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is FARN or HZD more profitable?

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Horizon Discovery Group plc (HZD.L)'s return on equity. Company Net Margins Return on Equity Return on Assets Faron Pharmaceuticals Oy N/A 45.13% -70.00% Horizon Discovery Group plc (HZD.L) N/A N/A N/A

Which has better valuation and earnings, VRP or FARN?

Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verona Pharma plc (VRP.L) N/A N/A N/A -£32.70 N/A Faron Pharmaceuticals Oy N/A N/A -£60.23M -£22.07 N/A

Is VRP or FARN more profitable?

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Verona Pharma plc (VRP.L)'s return on equity. Company Net Margins Return on Equity Return on Assets Verona Pharma plc (VRP.L) N/A N/A N/A Faron Pharmaceuticals Oy N/A 45.13% -70.00%

Do analysts rate FARN or BTG?

BTG has a consensus price target of GBX 160, indicating a potential upside of 32.23%. Given BTG's stronger consensus rating and higher possible upside, analysts clearly believe BTG is more favorable than Faron Pharmaceuticals Oy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Faron Pharmaceuticals Oy 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BTG 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is FARN or BTG more profitable?

Faron Pharmaceuticals Oy's return on equity of 45.13% beat BTG's return on equity. Company Net Margins Return on Equity Return on Assets Faron Pharmaceuticals Oy N/A 45.13% -70.00% BTG N/A N/A N/A

Does the media refer more to FARN or BTG?

In the previous week, BTG had 1 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 4 mentions for BTG and 3 mentions for Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy's average media sentiment score of 1.34 beat BTG's score of -0.15 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Faron Pharmaceuticals Oy 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BTG 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Faron Pharmaceuticals Oy (FARN) Competitors

GBX 46 -2.00 (-4.17%)

As of 12:14 PM Eastern

Compare

FARN vs. PRTC, HZD, VRP, SCLP, and BTG

Should you buy Faron Pharmaceuticals Oy stock or one of its competitors? MarketBeat compares Faron Pharmaceuticals Oy with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Faron Pharmaceuticals Oy include PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Scancell (SCLP), and BTG (BTG). These companies are all part of the "biotechnology" industry.

How does Faron Pharmaceuticals Oy compare to PureTech Health?

Faron Pharmaceuticals Oy (LON:FARN) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

1.6% of Faron Pharmaceuticals Oy shares are held by institutional investors. Comparatively, 34.6% of PureTech Health shares are held by institutional investors. 3.9% of Faron Pharmaceuticals Oy shares are held by company insiders. Comparatively, 13.4% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
PureTech Health	-2,355.32%	-31.98%	-13.39%

Faron Pharmaceuticals Oy has higher earnings, but lower revenue than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
PureTech Health	£4.66M	69.59	-£91.86M	-£46.00	N/A

PureTech Health has a consensus price target of GBX 508, indicating a potential upside of 281.38%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts plainly believe PureTech Health is more favorable than Faron Pharmaceuticals Oy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Faron Pharmaceuticals Oy	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Faron Pharmaceuticals Oy has a beta of 1.109, meaning that its share price is 11% more volatile than the broader market. Comparatively, PureTech Health has a beta of 0.788, meaning that its share price is 21% less volatile than the broader market.

In the previous week, Faron Pharmaceuticals Oy had 3 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Faron Pharmaceuticals Oy and 0 mentions for PureTech Health. Faron Pharmaceuticals Oy's average media sentiment score of 1.34 beat PureTech Health's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Positive
PureTech Health	Neutral

Summary

Faron Pharmaceuticals Oy beats PureTech Health on 8 of the 15 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Horizon Discovery Group plc (HZD.L)?

Faron Pharmaceuticals Oy (LON:FARN) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

In the previous week, Faron Pharmaceuticals Oy had 3 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 3 mentions for Faron Pharmaceuticals Oy and 0 mentions for Horizon Discovery Group plc (HZD.L). Faron Pharmaceuticals Oy's average media sentiment score of 1.34 beat Horizon Discovery Group plc (HZD.L)'s score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Positive
Horizon Discovery Group plc (HZD.L)	Neutral

1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 3.9% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

Summary

Faron Pharmaceuticals Oy beats Horizon Discovery Group plc (HZD.L) on 6 of the 9 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Verona Pharma plc (VRP.L)?

Verona Pharma plc (VRP.L) (LON:VRP) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A

In the previous week, Faron Pharmaceuticals Oy had 3 more articles in the media than Verona Pharma plc (VRP.L). MarketBeat recorded 3 mentions for Faron Pharmaceuticals Oy and 0 mentions for Verona Pharma plc (VRP.L). Faron Pharmaceuticals Oy's average media sentiment score of 1.34 beat Verona Pharma plc (VRP.L)'s score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.

Company	Overall Sentiment
Verona Pharma plc (VRP.L)	Neutral
Faron Pharmaceuticals Oy	Positive

1.6% of Faron Pharmaceuticals Oy shares are held by institutional investors. 3.9% of Faron Pharmaceuticals Oy shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Verona Pharma plc (VRP.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verona Pharma plc (VRP.L)	N/A	N/A	N/A
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%

Summary

Faron Pharmaceuticals Oy beats Verona Pharma plc (VRP.L) on 6 of the 8 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Scancell?

Scancell (LON:SCLP) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

1.5% of Scancell shares are owned by institutional investors. Comparatively, 1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 15.5% of Scancell shares are owned by company insiders. Comparatively, 3.9% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Scancell has higher revenue and earnings than Faron Pharmaceuticals Oy. Scancell is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	53.31	-£6.75M	-£0.55	N/A
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A

Scancell has a beta of 0.573, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.109, meaning that its stock price is 11% more volatile than the broader market.

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Faron Pharmaceuticals Oy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%

In the previous week, Faron Pharmaceuticals Oy had 3 more articles in the media than Scancell. MarketBeat recorded 3 mentions for Faron Pharmaceuticals Oy and 0 mentions for Scancell. Faron Pharmaceuticals Oy's average media sentiment score of 1.34 beat Scancell's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.

Company	Overall Sentiment
Scancell	Neutral
Faron Pharmaceuticals Oy	Positive

Summary

Scancell and Faron Pharmaceuticals Oy tied by winning 6 of the 12 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to BTG?

Faron Pharmaceuticals Oy (LON:FARN) and BTG (LON:BTG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Faron Pharmaceuticals Oy's return on equity of 45.13% beat BTG's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	45.13%	-70.00%
BTG	N/A	N/A	N/A

1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 19.3% of BTG shares are owned by institutional investors. 3.9% of Faron Pharmaceuticals Oy shares are owned by insiders. Comparatively, 19.8% of BTG shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BTG had 1 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 4 mentions for BTG and 3 mentions for Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy's average media sentiment score of 1.34 beat BTG's score of -0.15 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Faron Pharmaceuticals Oy	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BTG	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

BTG has a consensus price target of GBX 160, indicating a potential upside of 32.23%. Given BTG's stronger consensus rating and higher possible upside, analysts clearly believe BTG is more favorable than Faron Pharmaceuticals Oy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Faron Pharmaceuticals Oy	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BTG	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

BTG has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£22.07	N/A
BTG	£159.40M	1.22	N/A	£6.00	20.17

Summary

BTG beats Faron Pharmaceuticals Oy on 10 of the 12 factors compared between the two stocks.

Get Faron Pharmaceuticals Oy News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FARN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FARN vs. The Competition

Export

Metric	Faron Pharmaceuticals Oy	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£91.78M	£477.14M	£6.31B	£2.80B
Dividend Yield	N/A	3.86%	2.68%	6.07%
P/E Ratio	-2.08	3.14	21.13	365.58
Price / Sales	N/A	6,915.55	546.66	88,236.04
Price / Cash	20.00	13.13	27.44	27.89
Price / Book	0.02	84.89	9.95	7.74
Net Income	-£60.23M	-£96.07M	£3.56B	£5.89B
7 Day Performance	8.24%	1.87%	2.12%	0.93%
1 Year Performance	-81.60%	97.59%	36.38%	79.20%

Faron Pharmaceuticals Oy Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FARN Faron Pharmaceuticals Oy	N/A	GBX 46 -4.2%	N/A	-80.8%	£91.78M	N/A	N/A	34	Positive News
PRTC PureTech Health	1.4596 of 5 stars	GBX 137.60 +5.0%	GBX 508 +269.2%	+1.9%	£318.88M	£4.66M	N/A	300
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
VRP Verona Pharma plc (VRP.L)	N/A	N/A	N/A	N/A	£228M	N/A	N/A	22	Gap Up
SCLP Scancell	N/A	GBX 21.90 +4.3%	N/A	+130.9%	£217.93M	£4.71M	N/A	51	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:FARN) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Faron Pharmaceuticals Oy (FARN) Competitors

FARN vs. PRTC, HZD, VRP, SCLP, and BTG

How does Faron Pharmaceuticals Oy compare to PureTech Health?

Summary

How does Faron Pharmaceuticals Oy compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Faron Pharmaceuticals Oy compare to Verona Pharma plc (VRP.L)?

Summary

How does Faron Pharmaceuticals Oy compare to Scancell?

Summary

How does Faron Pharmaceuticals Oy compare to BTG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FARN vs. The Competition

Faron Pharmaceuticals Oy Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Faron Pharmaceuticals Oy (FARN) Competitors

FARN vs. PRTC, HZD, VRP, SCLP, and BTG

How does Faron Pharmaceuticals Oy compare to PureTech Health?

Do insiders & institutionals have more ownership in FARN or PRTC?

Is FARN or PRTC more profitable?

Which has stronger earnings & valuation, FARN or PRTC?

Do analysts prefer FARN or PRTC?

Which has more risk and volatility, FARN or PRTC?

Does the media prefer FARN or PRTC?

Summary

How does Faron Pharmaceuticals Oy compare to Horizon Discovery Group plc (HZD.L)?

Does the media favor FARN or HZD?

Do institutionals and insiders hold more shares of FARN or HZD?

Which has stronger earnings & valuation, FARN or HZD?

Is FARN or HZD more profitable?

Summary

How does Faron Pharmaceuticals Oy compare to Verona Pharma plc (VRP.L)?

Which has better valuation and earnings, VRP or FARN?

Does the media refer more to VRP or FARN?

Do institutionals and insiders have more ownership in VRP or FARN?

Is VRP or FARN more profitable?

Summary

How does Faron Pharmaceuticals Oy compare to Scancell?

Do insiders & institutionals believe in SCLP or FARN?

Which has preferable valuation & earnings, SCLP or FARN?

Which has more volatility & risk, SCLP or FARN?

Is SCLP or FARN more profitable?

Does the media prefer SCLP or FARN?

Summary

How does Faron Pharmaceuticals Oy compare to BTG?

Is FARN or BTG more profitable?

Do insiders and institutionals have more ownership in FARN or BTG?

Does the media refer more to FARN or BTG?

Do analysts rate FARN or BTG?

Which has stronger earnings & valuation, FARN or BTG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FARN vs. The Competition

Faron Pharmaceuticals Oy Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools